Search - tctmd.com

Displaying 301 - 320 of 409

Sort: Relevancy | Date

News Daily News

INR Test Strips Recalled Due to Inaccurate Measurements

Todd Neale

November 02, 2018

News Daily News

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Michael O'Riordan

November 01, 2018

News Daily News

Prescription Omega-3 Fatty Acids Cut Cardiovascular Events: REDUCE-IT

Shelley Wood

September 24, 2018

News Conference News ESC 2018

Aspirin Fails to Prevent CV Events in People at ‘Moderate’ Risk of Disease: ARRIVE

Shelley Wood

August 26, 2018

News Conference News ESC 2018

CLARIFY: No Survival Benefit With Beta-Blockers Beyond 1 Year Post-MI in Stable CAD

Shelley Wood

August 25, 2018

News Daily News

In Type 2 Diabetes, Five Risk Factor Targets Keep MI, Stroke, and Death in Check

Caitlin E. Cox

August 15, 2018

News Daily News

Real-world Analysis Suggests Apixaban Is Safest of the NOACs, Even for Patients With A-fib

L.A. McKeown

July 06, 2018

News Daily News

All-Cause Death Not Increased With Febuxostat Among Medicare Patients With Gout

Caitlin E. Cox

June 19, 2018

News Conference News EAS 2018

ORION 1 Data Show Lipoprotein-Lowering Beyond LDL Cholesterol With Injectable Inclisiran

Yael L. Maxwell

May 14, 2018

News Conference News SCAI 2018

Coronary Plaques in Psoriasis Patients Change After Treatment With Biologics

L.A. McKeown

May 01, 2018

News Daily News

To Cut CV Risk in Diabetes, Prescribe the Right Meds and Push for Lifestyle Changes

Michael O'Riordan

April 17, 2018

News Conference News ACC 2018

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

Michael O'Riordan

March 20, 2018

News Conference News ACC 2018

Gout Drug Febuxostat Linked to More CV Deaths Without Uptick in CV Events: CARES Trial

Caitlin E. Cox

March 14, 2018

News Conference News ACC 2018

Mixing Haircuts and Hypertension Rx a ‘Home Run’ for Blood Pressure Control

Todd Neale

March 12, 2018

News Conference News ACC 2018

Canakinumab Falls Short of Halting Progression to Diabetes in Patients at Risk: CANTOS

Michael O'Riordan

March 12, 2018

News Daily News

Bempedoic Acid Phase III Trial Meets Primary Endpoint for Cutting LDL Cholesterol

Yael L. Maxwell

March 08, 2018

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Shelley Wood

March 05, 2018

News Daily News

Maze of Prior Authorization for PCSK9 Inhibitors Poses Challenge to Prescribers

Yael L. Maxwell

January 24, 2018

News Daily News

Synopsis of New Hypertension Guidelines Renews Concerns and Controversy

L.A. McKeown

January 22, 2018

News Daily News

Ten Principles for Successful Treatment of HF With Reduced EF: New ACC Decision Pathway

Michael O'Riordan

January 02, 2018

Advertisement

INR Test Strips Recalled Due to Inaccurate Measurements

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Prescription Omega-3 Fatty Acids Cut Cardiovascular Events: REDUCE-IT

Aspirin Fails to Prevent CV Events in People at ‘Moderate’ Risk of Disease: ARRIVE

CLARIFY: No Survival Benefit With Beta-Blockers Beyond 1 Year Post-MI in Stable CAD

In Type 2 Diabetes, Five Risk Factor Targets Keep MI, Stroke, and Death in Check

Real-world Analysis Suggests Apixaban Is Safest of the NOACs, Even for Patients With A-fib

All-Cause Death Not Increased With Febuxostat Among Medicare Patients With Gout

ORION 1 Data Show Lipoprotein-Lowering Beyond LDL Cholesterol With Injectable Inclisiran

Coronary Plaques in Psoriasis Patients Change After Treatment With Biologics

To Cut CV Risk in Diabetes, Prescribe the Right Meds and Push for Lifestyle Changes

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

Gout Drug Febuxostat Linked to More CV Deaths Without Uptick in CV Events: CARES Trial

Mixing Haircuts and Hypertension Rx a ‘Home Run’ for Blood Pressure Control

Canakinumab Falls Short of Halting Progression to Diabetes in Patients at Risk: CANTOS

Bempedoic Acid Phase III Trial Meets Primary Endpoint for Cutting LDL Cholesterol

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Maze of Prior Authorization for PCSK9 Inhibitors Poses Challenge to Prescribers

Synopsis of New Hypertension Guidelines Renews Concerns and Controversy

Ten Principles for Successful Treatment of HF With Reduced EF: New ACC Decision Pathway

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content